As of 2025-05-14, the EV/EBITDA ratio of Astrazeneca Pharma India Ltd (ASTRAZEN.NS) is 80.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ASTRAZEN.NS's latest enterprise value is 198,190.90 mil INR. ASTRAZEN.NS's TTM EBITDA according to its financial statements is 2,447.63 mil INR. Dividing these 2 quantities gives us the above ASTRAZEN.NS EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 23.0x - 24.4x | 23.7x |
| Forward P/E multiples | 13.1x - 20.4x | 18.1x |
| Fair Price | 1,557.05 - 2,580.75 | 2,292.30 |
| Upside | -80.8% - -68.2% | -71.8% |
| Date | EV/EBITDA |
| 2025-05-09 | 79.45 |
| 2025-05-08 | 81.11 |
| 2025-05-07 | 81.39 |
| 2025-05-06 | 82.20 |
| 2025-05-05 | 82.87 |
| 2025-05-02 | 83.33 |
| 2025-04-30 | 86.50 |
| 2025-04-29 | 87.74 |
| 2025-04-28 | 88.73 |
| 2025-04-25 | 86.91 |
| 2025-04-24 | 89.40 |
| 2025-04-23 | 90.51 |
| 2025-04-22 | 89.37 |
| 2025-04-21 | 87.23 |
| 2025-04-17 | 86.92 |
| 2025-04-16 | 84.86 |
| 2025-04-15 | 88.55 |
| 2025-04-11 | 84.64 |
| 2025-04-09 | 80.11 |
| 2025-04-08 | 80.36 |
| 2025-04-07 | 79.02 |
| 2025-04-04 | 78.93 |
| 2025-04-03 | 80.00 |
| 2025-04-02 | 80.74 |
| 2025-04-01 | 84.55 |
| 2025-03-28 | 85.64 |
| 2025-03-27 | 84.86 |
| 2025-03-26 | 83.84 |
| 2025-03-25 | 83.84 |
| 2025-03-24 | 84.35 |
| 2025-03-21 | 85.88 |
| 2025-03-20 | 83.60 |
| 2025-03-19 | 78.73 |
| 2025-03-18 | 78.68 |
| 2025-03-17 | 76.69 |
| 2025-03-13 | 75.67 |
| 2025-03-12 | 76.55 |
| 2025-03-11 | 76.96 |
| 2025-03-10 | 75.26 |
| 2025-03-07 | 74.08 |
| 2025-03-06 | 74.12 |
| 2025-03-05 | 72.62 |
| 2025-03-04 | 73.00 |
| 2025-03-03 | 68.21 |
| 2025-02-28 | 66.19 |
| 2025-02-27 | 68.53 |
| 2025-02-25 | 68.52 |
| 2025-02-24 | 68.35 |
| 2025-02-21 | 68.16 |
| 2025-02-20 | 69.07 |